Apollomics has signed an exclusive collaboration and license agreement with GlycoMimetics for two acute myeloid leukaemia (AML) programmes.

Under the agreement, Apollomics received clinical development and commercialisation rights of GlycoMimetics’ uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, referred to as Greater China.

In turn, GlycoMimetics will receive an upfront cash payment of $9m. It will also be eligible for potential milestone payments that may amount up to $180m, as well as tiered royalties on net sales.

Developed by GlycoMimetics, uproleselan and GMI-1687 are E-selectin inhibitors.

Currently, uproleselan is under Phase III development programme in AML. It has also received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) to treat adult AML patients with relapsed or refractory disease.

GMI-1687 is designed for subcutaneous (SC) administration and observed to demonstrate the equivalent activity to uproleselan at an almost 250-fold lower dose. It is currently undergoing investigational new drug (IND)-enabling studies.

As part of the deal, Apollomics will develop, seek regulatory approvals and commercialise the two compounds in Greater China. It will procure uproleselan and GMI-1687 from GlycoMimetics, under a clinical and commercial supply agreement.

Both companies also agreed to collaborate on the preclinical and clinical development of GMI-1687.

Apollomics CEO Guo-Liang Yu said: “Our portfolio of assets is composed of highly specific, targeted agents, and we believe that the mechanism of action for uproleselan and GMI-1687 to selectively bind to E-selectin is the perfect complement to our pipeline.

“The work done by GlycoMimetics will allow Apollomics to leverage emerging data in AML and other hematologic malignancies, which uproleselan and GMI-1687 might be effective and beneficial for patients in Greater China.”

GlycoMimetics continues to hold all rights related to uproleselan and GMI-1687 outside Greater China.